oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study . J Clin Oncol 2010 ; 28 : 4697 – 4705 . 11 Hurwitz H Fehrenbacher L Novotny W . Bevacizumab
Search Results
Scott Ramsey and Veena Shankaran
Michael D. Stubblefield, Harold J. Burstein, Allen W. Burton, Christian M. Custodio, Gary E. Deng, Maria Ho, Larry Junck, G. Stephen Morris, Judith A. Paice, Sudhakar Tummala, and Jamie H. Von Roenn
: 3081 – 3094 . 5 Siegal T Haim N . Cisplatin-induced peripheral neuropathy: Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps . Cancer 1990 ; 66 : 1117 – 1123 . 6 Cassidy J Misset JL . Oxaliplatin
Metastatic Colon Cancer, Version 3.2013
Featured Updates to the NCCN Guidelines
Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Kristina M. Gregory, and Deborah A. Freedman-Cass
8% in the HIPEC group, mostly related to bowel leakage. In addition, long-term survival does not seem to be improved by this treatment as seen in follow-up results. 11 Importantly, this trial was performed without oxaliplatin, irinotecan, or
Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Kristina M. Gregory, and Deborah A. Freedman-Cass
older than 65 years and involved a period before the use of oxaliplatin-based therapies, 12 it is still an important piece of data to consider during the decision-making process regarding the use of adjuvant chemotherapy in patients with stage II
Presenters: Crystal S. Denlinger, Kristina A. Matkowskyj, and Mary F. Mulcahy
esophageal adenocarcinoma to chemotherapy with fluoropyrimidine and oxaliplatin (FU/leucovorin/oxaliplatin [FOLFOX] or capecitabine/oxaliplatin [XELOX]) ± nivolumab. The dual primary endpoints were overall survival (OS) and progression-free survival (PFS) for
Al B. Benson III, Alan P. Venook, Lynette Cederquist, Emily Chan, Yi-Jen Chen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Peter C. Enzinger, Alessandro Fichera, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Christina S. Wu, Kristina M. Gregory, and Deborah Freedman-Cass
, oxaliplatin, bevacizumab, cetuximab, panitumumab, ziv-aflibercept, ramucirumab, regorafenib, trifluridine-tipiracil, pembrolizumab, and nivolumab. 7 – 48 The putative mechanisms of action of these agents are varied and include interference with DNA
Efrat Dotan, Ilene Browner, Arti Hurria, and Crystal Denlinger
.13; 95% CI, 0.74–1.75). 38 With this limited overall benefit, adjuvant 5-FU for stage II colon cancer should be evaluated carefully in the older population and reviewed against competing comorbidities and causes of death. The Role of Oxaliplatin in
Andrew H. Ko and Margaret A. Tempero
+ oxaliplatin) versus Gem (gemcitabine) in non resectable pancreatic adenocarcinoma: Final results of the GERCOR/GISCAD Intergroup Phase III (Abstr) . In: Proceedings of the American Society of Clinical Oncology. New Orleans, LA : ASCO ; 2004 ; 23 : 314
Lucy X. Ma, Elan D. Panov, Michael J. Allen, Gail E. Darling, Jonathan C. Yeung, Carol J. Swallow, Savtaj S. Brar, Rebecca K. Wong, Patrick Veit-Haibach, Sangeetha N. Kalimuthu, Eric X. Chen, Raymond W. Jang, and Elena Elimova
ratio [HR], 0.653) and OS (71.7% vs 61.1%; HR, 0.669) with S-1 at 5 years. 14 The CLASSIC study, conducted in South Korea, China, and Taiwan, investigated adjuvant chemotherapy (8 cycles of capecitabine and oxaliplatin) following D2 gastrectomy compared
of capecitabine + oxaliplatin was added as an option in adjuvant therapy with a category 2A designation. Footnote “j” was clarified by adding “exclusive of those cancers that are MSI-H” to grade 3-4. Surveillance Chest
